H.C. Wainwright Reiterates Buy Rating on ADC Therapeutics (ADCT)

January 6, 2025 7:10 AM EST Send to a Friend
H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $8.00 price target on ADC Therapeutics (NYSE: ADCT).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login